Fulcrum Therapeutics Inc.

NASDAQ: FULC · Real-Time Price · USD
6.81
0.21 (3.18%)
At close: Aug 15, 2025, 3:59 PM
6.82
0.15%
After-hours: Aug 15, 2025, 04:10 PM EDT

Fulcrum Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
80M 2.81M 6.34M 19.16M
Cost of Revenue
1.59M n/a 2.41M 2.52M
Gross Profit
78.41M 2.81M 3.93M 16.65M
Operating Income
-21.9M -110.66M -112.56M -81.05M
Interest Income
n/a n/a n/a 207K
Pretax Income
-9.72M -97.33M -109.87M -80.85M
Net Income
-9.72M -97.33M -105.62M -78.33M
Selling & General & Admin
36.45M 41.67M 41.69M 30.52M
Research & Development
63.39M 71.8M 76.78M 69.7M
Other Expenses
2.06M n/a 2.69M 207K
Operating Expenses
101.9M 113.47M 118.48M 100.22M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
101.9M 113.47M 118.48M 100.22M
Income Tax Expense
n/a n/a -4.25M -2.52M
Shares Outstanding (Basic)
61.98M 61.31M 44.99M 35.36M
Shares Outstanding (Diluted)
61.98M 61.31M 44.99M 35.36M
EPS (Basic)
-0.17 -1.59 -2.35 -2.22
EPS (Diluted)
-0.17 -1.59 -2.35 -2.22
EBITDA
-18.24M -108.49M -109.72M -78.54M
EBIT
-19.83M -110.66M -112.13M -81.05M
Depreciation & Amortization
1.59M 2.17M 2.41M 2.52M